M
MetrioPharm
A pharmaceutical biotech company developing the first effective and safe therapy for chronic immune disorders
About MetrioPharm
MetrioPharm AG is a pharmaceutical development company specializing in therapies for chronic inflammatory diseases. Headquartered in Zurich with a research facility in Berlin, the company is pioneering a new class of self-regulating drugs aimed at reducing cellular oxidative stress, a key factor in chronic inflammation. Their lead compound, MP1032, is currently in Phase II clinical development and has shown both therapeutic efficacy and an excellent safety profile. MetrioPharm's primary focus is on Immune Mediated Inflammatory Diseases (IMIDs) such as psoriasis, arthritis, and multiple sclerosis. The company aims to provide patients with earlier treatment options that come with fewer health risks and side effects. MetrioPharm is also exploring the development of its MP1000 platform in an inhaled dosage form, which could further enhance treatment efficacy and patient compliance. The company serves a global market, targeting patients suffering from chronic inflammatory conditions. MetrioPharm's business model revolves around the research and development of innovative pharmaceutical compounds, which they aim to bring to market through clinical trials and regulatory approval processes. Revenue is generated through the commercialization of these drugs, either directly or through partnerships and licensing agreements with larger pharmaceutical companies.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2007
- Headquarters
- Zurich, Switzerland
- Employees
- 18
- Open positions
- None listed
- Dealroom signal
- 31.7/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Biotech and Pharma, Hard Tech, DT and LS, science-based, Swiss DT Biotech
- Business model
- Manufacturing
- Client focus
- b2b
Knowledge graph
More headlines
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| GRANT✓Other financing | Oct 2022 | $138K | — | Duchenne UK | ↗ |
| SERIES D✓Equity / VC | Dec 2018 | $18M | $73M | Undisclosed | ↗ |
Financials
Revenue, earnings and other financial measures where available. Years marked “E” are estimates.
Growth signals
Latest recorded traffic for MetrioPharm is 730 monthly website visits, down 43.8% over the last three months. MetrioPharm's team declined 14.3% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investments and acquisitions
Recent portfolio relationships for companies that also act as investors or acquirers.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Seed1 investor entered at this stage
Duchenne UK
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about MetrioPharm on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See MetrioPharm’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.